KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Research & Development (2016 - 2025)

Historic Research & Development for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $77.1 million.

  • Xenon Pharmaceuticals' Research & Development rose 3525.36% to $77.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.7 million, marking a year-over-year increase of 4203.85%. This contributed to the annual value of $210.4 million for FY2024, which is 2559.94% up from last year.
  • Xenon Pharmaceuticals' Research & Development amounted to $77.1 million in Q3 2025, which was up 3525.36% from $75.0 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Research & Development's 5-year high stood at $77.1 million during Q3 2025, with a 5-year trough of $16.3 million in Q1 2021.
  • In the last 5 years, Xenon Pharmaceuticals' Research & Development had a median value of $41.1 million in 2023 and averaged $40.7 million.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 10411.16% in 2023, then soared by 1198.0% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' Research & Development (Quarter) stood at $21.9 million in 2021, then skyrocketed by 59.14% to $34.8 million in 2022, then rose by 17.93% to $41.1 million in 2023, then soared by 44.79% to $59.5 million in 2024, then rose by 29.56% to $77.1 million in 2025.
  • Its Research & Development was $77.1 million in Q3 2025, compared to $75.0 million in Q2 2025 and $61.2 million in Q1 2025.